



Targeting Wnt Signaling in Cancer: Opportunities Abound If We Can Avoid the Sword of Damocles

Guest Editors:

Prof. Dr. Michael Kahn

Department of Cancer Biology
and Molecular Medicine,
Beckman Research Institute at
City of Hope, Duarte, CA 91010-
3000, USA

Dr. Keane Lai

Department of Molecular
Medicine, Beckman Research
Institute of City of Hope, Duarte,
CA 91010, USA

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editors

Dear Colleagues,

In the “Topic of Special Interest”, we propose to cover the role of Wnt signaling in cancer, likely with a focus on cancers in solid tumors, especially GI cancers. We will discuss the different driver mutations associated with Wnt-driven cancers (i.e., APC, beta-catenin, Axin, RNF43, etc.) and their association with various cancer types. We plan to also discuss the role of Wnt signaling on the tumor microenvironment and the tumor immune response. Finally, a discussion of efforts to pharmacologically target Wnt signaling to date, including problems and progress, is planned.

Prof. Michael Kahn

Dr. Keane Lai

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)